

ESG Summary Report
2023

MaxCyte®

Let's Build Better Cells Together.™

Forward-Looking Statements

This reports contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding expected total research and development expenses, features and potential impact of the company's products, the company's energy usage, and the company's expected commitment to working in partnership with all relevant stakeholders to make medicines accessible to more patients around the world. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with the timing of our customers' ongoing and planned clinical trials; the adequacy of our cash resources and availability of financing on commercially reasonable terms; general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and demand for our products. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 15, 2023, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available under the "SEC filings" page of the Investors section of our website at http://investors.maxcyte.com. Any forward-looking statements represent our views only as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Table of Contents

Our Approach to ESG

At MaxCyte, we have taken key steps to formalize our approach to environmental, social, and governance (ESG) issues. In April 2023, the Nominating & Corporate Governance Committee of our Board of Directors expanded its charter to include oversight of the company's ESG strategy and practices. At the management level, our President and Chief Executive Officer, Chief Financial Officer, EVP and General Counsel, and Senior Director of Investor Relations oversee our ESG initiatives and provide periodic updates regarding the ESG program to the Board of Directors.

To develop our ESG strategy, we partnered with external ESG experts to identify, evaluate, and prioritize ESG topics relevant to our business. This process was guided by leading ESG reporting standards, in particular the Sustainability Accounting Standards Board (SASB). We also incorporated analysis of third-party rating agency reports, peer benchmarking, and input from key stakeholders, such as investors and employees.

As we advance our ESG efforts, we will continue to assess and enhance our policies and processes. We look forward to providing further updates about our progress. For additional information, please also refer to our governance documents, SEC filings, and most recent proxy statement available at https://investors.maxcyte.com/.

Mission

We build trust with our customers, and together we leverage best-in-class technology and expertise to solve the toughest challenges in cell engineering, bringing hope to patients.

Our Products

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ instrument family, which is based on our proprietary Flow Electroporation® technology, has been designed to address the rapidly expanding cell therapy market from concept to clinic. We are dedicated to making meaningful differences in patients' lives by providing best-in class solutions that accelerate the development of cell-based medicines, providing potential significant time and cost savings for new treatments. Our technology platform has been involved in over 45 clinical trials to date.

MaxCyte has evolved the electroporation process from a single cuvette experiment to a Flow Electroporation® protocol ideal for genetic engineering at commercial scale. Higher transfection efficiency and increased cell viability compared to other approaches makes Flow Electroporation perfectly suited for large-scale therapeutic manufacturing. Because the complete workflow, from development to manufacturing, can be performed on a single platform, there is no need for repeat optimization and validation when progressing from concept to clinic. This results in accelerated timelines with the added benefit of reduced manufacturing cost. A more rapid, reliable, and safe therapeutic development pipeline can expedite therapies to patients, saving lives.

MaxCyte enables advancements to cell-engineering through the application of our patented delivery platform, our scientists' deep expertise, and our interactive and collaborative partnerships to relieve the burden of disease for patients and their families. We provide our cell-engineering platform to leading drug developers, biotechnology companies, and academic research centers engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. Our goal is to rapidly drive our partners' development efforts forward through to commercialization cost-effectively and with lowered risk.

At MaxCyte, we recognize that it takes so much more than innovative technology to bring a new therapy to market — it takes a multifaceted, experienced, and adaptable team who know how to direct scientific and product innovation into novel medicines. This is why we form partnerships instead of simply selling an instrument. We support our partners by offering access to our entire scientific and technical teams and broad intellectual property (IP) portfolio, and through our non-exclusive licensing approach, we are able to simultaneously support multiple organizations to leverage our technology. Scientific inquiry and innovation are just beginning to unravel the complexities of cells, their regulation, and their relationship to disease, and our full service approach provides tools to discover new approaches for therapeutic intervention and possibly curative solutions. Our experienced team of application scientists work directly with partners to solve cell engineering problems and recommend continuous process improvements. Our FDA Master File and Technical Files also assist our partners in streamlining the development and regulatory process so they can unlock the potential of their products.

Annual R&D Spend (millions)



We continue to invest significantly in research and development for our products as we enhance existing features develop and collect more data to support their use in various applications. To ensure that our partners have access to our products, we expanded our manufacturing operations and relocated to a new facility in Rockville, Maryland so that we can meet increased demand.

We know there is more work to be done, and we believe that partnerships and collaborations are critical to expanding access to therapies. We remain committed to working in partnership with all relevant stakeholders to make our therapies accessible to more patients around the world.

Value for Patients Initiative

In addition to our goal of supporting our partners' development of innovative medicines for patients, we are also committed to understanding how we can create value for patient communities more broadly. We are keenly aware that there are many challenges that exist in healthcare access, equity, and adoption, including the unique barriers that patients may face in the ability to benefit from cell and gene therapies.

We launched the Value for Patients Initiative in 2021 to better understand the different challenges that discrete patient populations may face with current standards of care as well as forthcoming cell and gene-based medicines. As part of our commitment to improving lives, we strive to enhance our understanding of the patients, their diseases, and their journeys. The initial goal of the initiative is to develop an understanding of the potential social, racial, economic, and bioethical challenges related to developing gene and cell therapies. With this, we are able to educate and empower our employees with knowledge to better understand and help create trust with various patient communities. This initiative provides an educational forum that covers topics including medical racism, equity of access to medicines, clinical trial diversity, compassionate use in cell and gene therapy, and other issues specific to key stakeholders. For example, an early focus of our initiative has been on patients suffering from sickle cell disease, who suffer from a lack of available treatment options because investment in new therapies has been historically disregarded. Our partners currently have a variety of programs focused on developing therapies for sickle cell disease, and we have developed an array of educational forums and resources for our employees to learn about the sickle cell patient journey.

We have also developed relationships with key opinion leaders who focus on racial disparities and equity of access in healthcare, including: Amanda J. Calhoun, MD, MPH, Psychiatry resident at Yale University, who studies the mental health effects of racism on children and adolescents; Arthur L. Caplan, PhD, Professor of Bioethics at New York University Grossman School of Medicine; and Alison Bateman-House, PhD, Assistant Professor at New York University Grossman School of Medicine, whose research areas include ethics and policy as well as expanding diversity in clinical trials. Our Value for Patients advisory group also includes key subject matter experts, such as Vivien Sheehan, MD, PhD, Associate Professor of Pediatrics at Children's Healthcare of Atlanta and Emory University School of Medicine, where she is the Director of Translational Sickle Cell Disease Research. Our advisors are committed to helping us understand the social, racial, economic, and bioethical challenges related to developing cell and gene therapies so that we can proactively participate in efforts to ensure that these novel treatments reach patients.

Our CEO is an executive committee and board member of the Biotechnology Innovation Organization (BIO), the world's largest advocacy association for the biotechnology industry, and supports the organization's advocacy efforts such as the Workforce Development, Diversity, and Inclusion initiative. These efforts will allow us to build trust with underserved populations and promote better understanding of cell-based medicines.

Supporting Therapy Development for Rare Disorders and Diseases

We strive to expand access to cell therapies for all patients, regardless of disease or disorder. A recent study estimated that there are over 10,000 distinct rare diseases affecting 400 million people worldwide, yet only 500 of these disorders have available treatment options. We not only support organizations developing treatments for large indications but also support companies developing therapies to treat rare and ultra-rare diseases that have few or no treatments.

For example, we have partnered with Curamys, a biotechnology company that develops cell and gene therapies using cell fusion technology to treat rare intractable diseases, such as Duchenne muscular dystrophy and amyotrophic lateral sclerosis. We signed a partnership agreement with Curamys at the end of 2022 that provides worldwide non-exclusive clinical and commercial rights, thereby enabling Curamys to reach more patients living with these rare diseases.

Pricing

Our business model varies based on the activity of the end customer, such as whether they are a translational research center, an academic center, a company focused on drug discovery, or a company engaged in cell therapy development. Each our instruments have different price points based on their relative features. In some cases, we adjust our fee structures for companies that target rare diseases and disorders to better enable these partnerships.

Product Quality

Producing high-quality products is integral to our mission to improve patient outcomes. As we expand our manufacturing operations and engineering capabilities, we are focused on establishing best-in-class quality processes and building a culture of continuous improvement.

Our ExPERT instruments and disposables are manufactured under current good manufacturing practice (cGMP) processes and our Quality Management System (QMS) is certified to ISO 9001. Several components for our products are fabricated by third party manufacturers, who we also validate for quality control and compliance purposes. A third-party auditor performs a surveillance audit of our QMS annually and a recertification audit every three years. All relevant employees receive training about the QMS upon hire and annually thereafter.

We do not engage in directly regulated activities nor do we produce regulated medical devices that interact with patients. We nevertheless strive to go above and beyond the quality and regulatory needs of our customers. We use medical-grade materials for all our products and have implemented quality requirements into our design controls across all stages of product development. All our instruments have obtained applicable certifications pertaining to safety and EMC requirements for electrical laboratory equipment, such as IEC 61010 and EN61326. Our instruments have received certificates of compliance from the CSA Group and are CE marked, indicating conformity to relevant EU directives for Electrical Equipment for Laboratory Use. As of May 2023, we have had no product recalls and no FDA enforcement actions taken in response to any violations.

Supply Chain Management

As our business grows, we have invested in increasing our manufacturing capacity and enhancing our supply chain management and quality practices. We continually assess our supply chain to ensure availability of components, our ability to respond to customer demand for our products, and our ability to qualify multiple suppliers. Our new headquarters in Rockville, Maryland has allowed us to expand our instrument and disposables manufacturing operations from research and clinical scale to commercial scale. This provides us with the ability to build in redundant manufacturing capacity and have more secure supply of materials to meet our customers' and partners' needs.

We strive to ensure that our products are always available and never on backorder. To date, we have achieved this through well-managed relationships with targeted suppliers that maintain high standards for quality, especially for single-source critical components. We engage in regular dialogue with our most critical suppliers to ensure their ability to deliver key materials for our operations, in particular for materials needed to produce the disposables our customers rely on to conduct clinical trials enabled by our platform. We also mitigate against potential supply shortages from single source suppliers by holding adequate inventory on hand to continue our manufacturing processes, which can include multiple years of safety stock for some critical components.

We plan to continue the diversification of our supply chain as part of our growth plans. In approving new suppliers, we prioritize suppliers that participate in third-party audit programs for product quality, such as ISO 9001. We have previously ended our relationship with certain suppliers for not meeting our quality standards. As of March 2023, 95% of our Tier 1 suppliers are certified to ISO 9001, ISO 13485, or similar third-party audit standards. Once we determine that a supplier can meet our quality requirements, we also look for ways the supplier can help us achieve efficiency objectives and environmental impact reductions. For example, reducing transport times and distances for raw materials is a key consideration of our supplier selection process.

Maintaining Traceability

As part of our QMS, we have enhanced traceability and control procedures for our devices that are aligned with the stringent requirements for medical devices. We maintain full traceability of raw materials and maintain thorough records. We assign lot and serial numbers for our instruments and disposables so that individual components can be identified, withdrawn from the field, and traced back to their supplier in the event of any product-related issue.

Number of Full-Time Employees





Our People

Our workforce has deep domain expertise across a range of scientific, engineering, regulatory, and business disciplines, allowing us to foster a scientifically-minded and customer-focused culture. Our cutting-edge technology and innovative solutions have enabled us to attract and retain top scientific and technical talent. As of December 31, 2022, we had 125 full-time employees, including 68 with advanced degrees and 25 with Ph.D. degrees. We believe that our diverse, multidisciplinary employee base provides us with a significant competitive advantage and enhances our ability to deliver new therapies to patients.

We strive to create an environment where all our employees are valued and empowered to make a difference. Our leadership encourages honest, open, and regular communication, building a foundation of trust and aligning employees with the company's goals. We've created a team-oriented, inspiring work environment where diverse ideas are valued and appreciated, bringing out the best in our employees. We aim to recruit talented, highly motivated individuals who can help advance our technology. We expect our employees to embody our Core Values:

1. We value and respect each other, our partners, and patients
2. We are undaunted in our commitment to relieving the burden of disease
3. We dig deep, working together to understand the problem, and always find a way
4. We stay curious and connected, and never get complacent
5. We approach each person, each situation with empathy and transparency
6. We take pride in the excellence of our technology and the expertise we deliver

Benefits

To attract, retain, and reward our personnel and motivate them to perform to the best of their abilities, we offer a competitive salary and benefits package*, including:

- Equity compensation and corporate incentive bonus plans for all full-time employees
- 401(k) Retirement Plan
  - Includes a company match of 50% of first 10% of employee contributions and the match is 100% vested immediately
- Medical, Dental, and Vision Insurance
  - Includes a "No Cost" option for employees and their families
- Life and Accidental Death & Dismemberment (AD&D) Insurance
- Short- and Long-Term Disability Insurance
- Long-Term Care Insurance
- Flexible Spending Account (FSA)
- Health Savings Account (HSA)
- Employee Assistance Program (EAP)
- Identity Theft Protection Insurance
- Tuition Reimbursement Program
  - Provides up to $4,000 to cover tuition and related fees for full-time employees in any given calendar year
- Tuition Loan Program
  - Provides up to $2,000 loan to cover tuition and related fees for full-time employees at the beginning of each semester
- Employee Referral Program
  - Employees may receive up to a $3,000 bonus for referring candidates who are hired for eligible positions
- 1 paid volunteer time off (VTO) day

** Employees in the United States who work a minimum of 30 hours per week are eligible for benefits listed above. Global employees are eligible for similar benefits as appropriate by region.*

We recognize and reward high performing employees through our spot award program. This program is widely used and enables any MaxCyte employee to nominate another employee for above and beyond efforts.

Gender Percentage (data as of January 2023)



We acknowledge as a company that we must hold true to our values and treat each other with acceptance, care, and respect. We must hold one another accountable, and we must help break down barriers.

Employee Engagement and Retention

In 2022, we conducted an employee engagement survey that was designed to gather feedback about four key pillars of our human capital management strategy: Leadership; Culture; Innovation; and Career Development. This survey had a 62% overall response rate. 97% of respondents agreed or strongly agreed that MaxCyte's Leadership and Culture make the company a great place to work; 93% of respondents agreed or strongly agreed that Career Development and Innovation at MaxCyte make the company a great place to work. We believe that our efforts to engage and retain our employees have contributed to our ability to maintain a voluntary turnover rate between 5.5% and 7% during each of the past four years, well below the industry average. One of our key 2023 human capital development goals is to maintain our voluntary turnover rate at or below 10%.

Workplace Development, Diversity, and Inclusion (WDDI)

At MaxCyte, we are an equal opportunity employer and are committed to fostering workplace development, diversity, and inclusion (WDDI) within our own organization and across the biotechnology industry. We are dedicated to being at the forefront of efforts to develop a diverse and talented global workforce, and we understand the value that diversity contributes to the culture and success of any business. Diverse teams enhance collaboration, are more accepting of differences, and are also more effective in the global environment in which we operate, enabling the promise of next-generation cell and gene-editing therapies around the globe.

To that end, we affirmatively support the WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, patients, and the communities where we operate. To support our recruitment efforts, we plan to launch an internship program and expand our university recruiting activities to help build a pipeline of future talent. In 2023, we plan to gather additional workforce diversity metrics and further develop and implement our diversity strategy.

Ethics & Compliance

Overview

MaxCyte is committed to maintaining the highest standards of business conduct and ethics. We promote integrity across the organization and conduct our affairs with honesty. We strive to follow both the spirit and letter of all applicable laws and regulations and expect our employees to understand the legal and regulatory requirements applicable to their activities.

Our Code of Conduct and Ethics (the Code) lays the foundation of our compliance program and applies to all officers, directors, and employees. The Code describes in detail the various elements of our compliance program, including:

- Honest and Ethical Conduct
- Legal Compliance
- Insider Trading
- Compliance with International Business Laws
- Antitrust
- Environmental Compliance
- Conflicts of Interest
- Maintaining Corporate Books, Records, Documents, and Accounts; Financial Integrity; Public Reporting
- Gifts and Entertainment
- Confidentiality
- Compliance Resources and Reporting Possible Violations of the Code
- Anti-Corruption Policy and Foreign Corrupt Practices Act (FCPA) Compliance

Our Executive Vice President and General Counsel is responsible for overseeing our compliance program and promoting an atmosphere of responsible and ethical conduct. The Audit Committee of our Board of Directors is responsible for overseeing the company's efforts to monitor compliance with applicable laws and rules, as well as the Code. Our EVP and General Counsel provides reports on the status of the compliance program to the Audit Committee at least quarterly. The Audit Committee is specifically tasked with reviewing the company's controls for preventing bribery and corruption, and for investigating any complaints regarding audit and accounting procedures. Additionally, the Nominating and Corporate Governance Committee of the Board periodically reviews and assesses the Code and recommends any changes as appropriate for consideration by the full Board.

To facilitate compliance, new employees receive a copy of the Code upon hire. We have also adopted other policies to support our compliance program, including an Anti-Bribery and Corruption Policy and a Whistleblower Policy. The Code and other compliance policies are available to all employees through our intranet. We are developing a training program for our Code, which we expect to launch in 2023. Going forward, we plan to implement other trainings covering our Anti-Corruption policy, the Foreign Corrupt Practices Act, our sexual harassment policy, and diversity, equity, and inclusion (DE&I) for all employees through an external training platform.



Fair Dealing and Ethical Marketing

We expect our employees to deal fairly with all our stakeholders, including customers, suppliers, partners, and regulators. We review all marketing materials with our scientific team and our EVP and General Counsel prior to distribution. Our sales representatives undergo semiannual trainings on good sales practices, which promote compliance with false marketing and anti-bribery laws.

Reporting Violations of the Code and Other Compliance Policies

We are committed to complying with applicable laws and regulations and providing a workplace conducive to open discussion of our business practices. We encourage every employee to promptly report any complaints regarding potential compliance concerns and we strictly prohibit unlawful discrimination or retaliation against anyone who makes a compliance complaint in good faith. While our employees are free to discuss any concerns with their supervisor or the General Counsel, we have also established mechanisms for employees to anonymously report a complaint through our compliance hotline and email, which is managed by a third-party, EthicsLine.

As part of our Whistleblower Policy for Accounting and Auditing Matters, we have also established a separate tool for employees who wish to anonymously issue complaints regarding accounting and auditing procedures. We promptly investigate all complaints we receive. If we determine that a violation has occurred, we will take appropriate corrective and disciplinary action with respect to the person involved and will take steps to remedy any violation.

Information Security

Our information security program is overseen by our Senior Director of Information Systems, who reports on the status of the program to the executive team. Additionally, the Audit Committee of the Board of Directors is responsible for overseeing risks relating to data privacy, technology, and information security and receives reports from IT and business personnel responsible for cybersecurity risk management at least quarterly.

We process personally identifiable information (PII) and other sensitive information in the course of our business. However, we do not deal directly with protected health information (PHI) because we are one step removed from patients. Therefore, we are not considered to be a covered entity under the Health Insurance Portability and Accountability Act (HIPAA). Our information security practices consist of an adaptive information lifecycle approach, in which we collect and centralize critical data including any data that would be potentially considered to be PII or PHI. We follow a defined plan for the retention, processing, disclosure, and destruction of data

and require our cloud vendors to comply with our data retention policies. For more information about our approach to protecting sensitive data, please refer to our Privacy Policy.

We utilize both onsite and cloud storage systems to secure our data. We have also deployed technical and physical safeguards, including encryption at rest and multi-factor forms of identification for physical access to facilities. We conduct manual and automated audits of our asset management and data classification practices, including monthly vulnerability assessments.

We maintain an information security risk insurance policy, which we renewed in 2022 after completing a technical audit. As of May 2023, we have not had any data breaches. We raise employee awareness and cultivate cybersecurity competency through monthly phishing simulations, quarterly information security trainings, and educational exercises with members of the executive management team. To further support our information security policies, we have aligned our program with the NIST Cybersecurity Framework and are currently evaluating the steps required to achieve ISO 27001 certification in the coming years.

Environment

It is our policy to conduct our business in an environmentally responsible way that minimizes environmental impacts. We have established design procedures and operational processes to reduce the impact of our products and promote sustainable practices across our organization. While we are early in our journey, we are collecting and analyzing key data to better understand our environmental footprint and inform our strategy going forward.

Facilities

In 2022, we moved into a new 67,000 square-foot facility in Rockville, Maryland that significantly increases our in-house manufacturing capacity, as well as research and process development lab space. This investment represents a major milestone in MaxCyte's growth and our ability to support customers and partners in their journey through therapeutic development to commercialization. By bringing more manufacturing in-house, we are able to reduce the amount of time needed for our products to reach end users and provide flexibility to ensure that we can meet our partners' needs in providing therapies to patients. We also collaborate with our suppliers to identify opportunities to reduce transport times and distances for raw materials.

We have adopted automated manufacturing processes at our new facility to use resources more efficiently and better manage our environmental footprint. For example, we have installed LED lighting and high-efficiency HVAC systems to help minimize power consumption.

Product Design & Lifecycle Management

When designing and developing new products, we are committed to incorporating environmentally friendly materials and processes. For example, we have incorporated DEHP-free materials in our products, and we try to utilize recyclable packaging materials where possible. Our consumable products contain biocompatible materials for patient safety and are engineered with a design focus on minimizing size and the amount of plastic used while still achieving high quality function and minimal cell loss. The potential for cell loss is further lowered through our efforts to reduce the size of our consumable product bags and tubing.

Our newest ExPERT instruments are an integrated system which incorporates the computer and interface display as opposed to a two-piece system. This instrument configuration reduces the amount of plastic and other materials used in the manufacturing process. Our newest systems are Restriction of Hazardous Substances (RoHS) compliant through our efforts to eliminate the use of any of the ten substances restricted by the directive.

Reducing energy consumption is a key consideration in our product design process and we have integrated power saving features into the design architecture of our products.

Commitment to Environmental Compliance

We are committed to minimizing and, if practicable, eliminating the use of any substance or material that may cause environmental damage. We comply with all applicable environmental laws and regulations and dispose of all our waste through safe and responsible methods. We have established sufficient procedures to ensure the safety of our employees and expect all our employees to comply with these policies.

MaxCyte®

Let's Build Better Cells Together.™

www.maxcyte.com